Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in microsatellite stable (MSS) Metastatic Colon Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 May 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.
- 13 Feb 2018 New trial record